GH Research (GHRS) Non-Current Assets (2021 - 2026)
GH Research (GHRS) posted quarterly Non-Current Assets of $134.2 million for Q4 2025, down 16.14% year-over-year from $160.1 million in Q4 2024, and up 1756.21% quarter-over-quarter from $7.2 million in Q3 2025.
GH Research (GHRS) Non-Current Assets (2021 - 2026) Analysis & Trends
GH Research's Non-Current Assets history runs 5 years deep, the most recent figure standing at $134.2 million for Q4 2025.
- In Q4 2025, Non-Current Assets fell 16.14% year-over-year to $134.2 million; the TTM figure through Dec 2025 stood at $134.2 million (down 16.14% YoY), while the FY2025 annual figure was $134.2 million, down 16.14% from the prior year.
- Non-Current Assets for Q4 2025 stood at $134.2 million, up from $7.2 million in the prior quarter.
- The five-year high for Non-Current Assets was $187.0 million in Q4 2023, with the low at $73000.0 in Q3 2021.
- The 5-year median for Non-Current Assets is $55.6 million (2024), against an average of $62.5 million.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets surged 104272.84% in 2023, then sank 83.81% in 2025.
- GH Research's Non-Current Assets stood at $122.1 million in 2021, then retreated by 29.7% to $85.8 million in 2022, then soared by 117.91% to $187.0 million in 2023, then retreated by 14.41% to $160.1 million in 2024, then declined by 16.14% to $134.2 million in 2025.
- Business Quant data shows GHRS's Non-Current Assets at $134.2 million in Q4 2025, $7.2 million in Q3 2025, and $19.5 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.96 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 294.93 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.96 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.76 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 18.06 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 938.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 468.65 Mn |
| 10 | GH Research | 2.02 Bn | 1.68 Bn | - | 3.53 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.53 Mn |
| Dec 31, 2025 | 134.24 Mn |
| Sep 30, 2025 | 7.23 Mn |
| Jun 30, 2025 | 19.55 Mn |
| Mar 31, 2025 | 25.79 Mn |
| Dec 31, 2024 | 160.07 Mn |
| Sep 30, 2024 | 44.67 Mn |
| Jun 30, 2024 | 54.07 Mn |
| Mar 31, 2024 | 57.11 Mn |
| Dec 31, 2023 | 187.02 Mn |
| Sep 30, 2023 | 68.53 Mn |
| Jun 30, 2023 | 73.87 Mn |
| Mar 31, 2023 | 84.54 Mn |
| Dec 31, 2022 | 85.82 Mn |
| Sep 30, 2022 | 84,000.00 |
| Jun 30, 2022 | 86,000.00 |
| Mar 31, 2022 | 81,000.00 |
| Dec 31, 2021 | 122.08 Mn |
| Sep 30, 2021 | 73,000.00 |